QuaCell Biotechnology Secures Nearly RMB 200 Million in Series B Funding to Advance Cell Culture Media Portfolio

Recently, Zhongshan Kangtian Shenghe Biotechnology Co., Ltd. announced the completion of its Series B financing round, raising nearly RMB 200 million. This round of investmentLed by Zhongke Kechuang, Huangpu Medical Fund, and Chuanliu Investment, with follow-on investments from Queshan Investment, Deqian Investment, Xiangshang Investment, Zhongshan Health Industry Fund, Huaying Investment, Taikang Investment, and other institutions, as well as existing shareholders.. This round of financing will be used to intensify product research and development, enhance technological innovation, and improve production capacity as well as the ability to fulfill high-standard industrial orders.

Representatives of Investment Institutions in This RoundXie Yong, CEO of Zhongke KechuangStatement: As the wave of domestic substitution for core raw materials gains momentum, we are full of confidence in growing alongside Kangsheng Biotech’s exceptional founding team. We also hope that by investing in key projects within the industrial chain, such as Kangsheng Biotech, we can promote self-reliance and controllability in the biopharmaceutical supply chain, address weaknesses in the industrial and supply chains, and establish a comprehensive biopharmaceutical supply chain system in the Guangdong-Hong Kong-Macao Greater Bay Area.

Representatives of Investment Institutions in This RoundLiu Fei, Huangpu Medical FundIt is stated: Having been in operation for just over three years, the Kangsheng team has already achieved a considerable scale and earned a strong reputation within the industry. We are delighted to collaborate with such a team and believe that, with additional capital support, expanded production capacity, and talent acquisition, Kangsheng Bio will undoubtedly become a key core supplier in the biopharmaceutical industry chain in China and globally.

Representatives of Investment Institutions in This RoundLu Gang, Partner at Chuanliu Investment ManagementStatement: We are delighted to see that, under the leadership of its three experienced founders, Kangsheng Biotech has successfully developed multiple commercial host cell line platforms, as well as stable, high-yield platform culture media, serving a large number of biopharmaceutical companies and biopharmaceutical CDMOs both in China and abroad. The investment in Kangsheng holds profound significance for Chuanliu’s investment portfolio. We look forward to working hand in hand with the Kangsheng team and other shareholders to drive the company’s rapid growth, empower pharmaceutical innovation, and accelerate industry development.

Pan Honghui and Wu Fan, Co-founders of Kangsheng BiotechStatement: We sincerely appreciate the investors’ recognition of Kangsheng’s past achievements and future strategic development. Moving forward, we will further focus on the research and development of core raw materials for protein antibody drugs, gene and cell therapies, and vaccine applications, as well as the development of technical services and the expansion of future production capacity. The Kangsheng team remains committed to providing high-quality products and services to our customers, striving wholeheartedly to support the development of China’s biopharmaceutical industry.

Guangdong Zhongke Kechuang Venture Capital Management Co., Ltd. (hereinafter referred to as “Zhongke Kechuang”) was established in July 2009. It is one of the first asset management institutions in China to engage in private equity fund investment and management businesses, including equity investment and venture capital. Upholding its corporate mission of “Empowering Scientific and Technological Innovation for Greater Efficiency and Enabling More Precise Investment,” Zhongke Kechuang is committed to developing into a boutique venture capital firm with deep roots in the Guangdong-Hong Kong-Macao Greater Bay Area, adopting an “orchardist” approach to nurturing startups. Currently, it manages 49 private equity funds with a total scale exceeding RMB 15 billion. The firm focuses on four key industrial sectors: pharmaceuticals, healthcare and general wellness; advanced manufacturing; intelligent technology; and semiconductors. To date, it has invested in over 100 high-growth sci-tech enterprises, 32 of which have successfully completed initial public offerings (IPOs).

Guangzhou Huangpu Biopharmaceutical Fund Management Co., Ltd. (hereinafter referred to as “Huangpu Biopharma Fund”) is a fund management company jointly established by Guangzhou Development District Holding Group, BeiGene, Leading Capital, and Guoju Venture Capital. Currently, Huangpu Biopharma Fund manages one fund. Leveraging the advantageous resources of its shareholders—such as BeiGene’s biopharmaceutical industry resources, Guangzhou Development District Holding Group’s government resources, and Leading Capital’s investment expertise—the fund focuses on early- to mid-stage projects, with particular emphasis on innovative drugs, medical devices, and healthcare informatics.

Chuanliu Investment is a professional investment firm focused on the new materials sector. Its fund investors include leading domestic and international materials companies as well as renowned professional institutional investors. Chuanliu Investment concentrates on key materials and technologies that drive industrial development. The products and technologies of its portfolio companies are widely applied in new energy, electronics, semiconductors, sustainable development, life sciences, and other broad industrial and consumer upgrade sectors. By leveraging its professional investment capabilities combined with industry resources, Chuanliu Investment is dedicated to identifying and supporting high-growth technology enterprises. It drives fundamental growth through technological innovation, industrial upgrading, and enhanced social value, while striving to create long-term value for its investors, portfolio companies, and society at large.

Zhongshan Health Technology Industrial Base Investment Management Co., Ltd. is a wholly-owned subsidiary of Zhongshan Health Base Group Co., Ltd., focusing on investments in the health industry. The company’s core team has over 15 years of deep expertise in the health sector, with extensive experience in investment promotion, asset management, and equity investment within the health industry, demonstrating professional judgment in evaluating health-related projects. To date, Health Base Investment Company has participated in establishing multiple sub-funds dedicated to the broader health industry and has made direct investments in numerous high-quality projects, committed to fostering the ecological development of Zhongshan’s health industry.

Zhongshan Torch Huaying Investment Co., Ltd. is a state-owned comprehensive financial investment company established with the approval of the Administrative Committee of Zhongshan Torch Hi-Tech Industrial Development Zone. The company is primarily engaged in the management of industrial guidance funds, equity investment, financial leasing, financing guarantees, and sci-tech finance within the Torch Development Zone. Leveraging its state-owned shareholder background, Huaying Investment focuses on integrating local government resources with high-potential startup projects in the zone. It prioritizes sectors such as pharmaceuticals and general health, optoelectronics, semiconductors, new energy, electronic information, and high-end equipment manufacturing, guiding capital toward key areas of the Torch Zone. By building a comprehensive financial platform for the Zhongshan Torch Hi-Tech Industrial Development Zone, the company is committed to promoting regional economic development and industrial upgrading.

QuaCell Biotechnology Co., Ltd. is a rapidly growing global biotechnology company headquartered in Zhongshan, within the Guangdong-Hong Kong-Macao Greater Bay Area. The company currently operates a modern biomedical innovation service platform spanning approximately 7,000 square meters, integrating cell culture media development and production, cell line development, and GMP pilot-scale manufacturing. Adhering to ISO and GMP regulatory standards, QuaCell Biotechnology specializes in the research and manufacture of cell culture media, providing critical raw materials to global biopharmaceutical and gene therapy enterprises. With a strong customer-centric focus, the company offers integrated services from DNA to GMP production that comply with FDA and NMPA requirements, earning the recognition and trust of nearly 100 biopharmaceutical and biotechnology clients both domestically and internationally.